The FDA decision on Bristol-Myers Squibb Co.’s (BMY) Sotyktu in the expanded indication of treatment of adults with active psoriatic arthritis is due on March 6, 2026.Sotyktu, which selectively targets and blocks tyrosine kinase 2 (TYK2), is an oral prescription pill already approved in the U.S. and numerous countries worldwide for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.In the pivotal clinical trials evaluating Sotyktu in adults with active psoriatic arthritis, a significantly higher percentage of patients treated with Sotyktu achieved an ACR20 response - defined as at least a 20% improvement in disease signs and symptoms - at 16 weeks compared with those receiving placebo.The drug generated $291 million in 2025 sales, up 19% from 2024.BMY closed Tuesday’s (Feb.24, 2026) trading at $61.60, up 0.57%.